/* 배경화면 투명도 제거 설정 */

[AHA 2012] Impact of Angiotensin Receptor Blocker on Development of Glucose Intolerance and New-onset Diabetes Mellitus in Asian Population


Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation.

Core 2. Epidemiology and Prevention of CV Disease: Physiology, Pharmacology and Lifestyle

Session Title: Diabetes Mellitus and CVD: Prevention and Management I

Abstract 19071: Impact of Angiotensin Receptor Blocker on Development of Glucose Intolerance and New-onset Diabetes Mellitus in Asian Population

Ji Young Park1; Seung Woon Rha2; Jae Woong Choi1; Sung Kee Ryu1; Byoung Geol Choi2; Se Yeon Choi2; Sung Il Im2; Sun Won Kim2; Jin Oh Na2; Seong Woo Han2; Cheol Ung Choi2; Hong Euy Lim2; Jin Won Kim2; Eung Ju Kim2; Chang Gyu Park2; Hong Seog Seo2; Dong Joo Oh2

1 Cardiology department, Eulji Univ, Eulji General Hosp, Seoul, Korea, Republic of
2 Cardiovascular Cntr, Korea Univ Guro Hosp, Seoul, Korea, Republic of

Background; Angiotensin receptor blocker (ARB) is being extensively used to control hypertension. But, there have been limited data whether ARB is associated with increased incidence of new-onset diabetes mellitus (DM) or impaired glucose intolerance (IGT).

Methods; We investigated total 13,561 patients (pts) that was glycerate hemoglobin level < 6.0% and fasting glucose level < 124 mg/dL (ARB therapy group=3421 and control group=9808) from January 2004 to February 2012. To adjust potential confounders, a propensity score matched analysis was performed using the logistic regression model. The primary end-point was the cumulative incidence of new-onset DM, IGT, and impaired fasting glucose (IFG). Also, multivariable cox-regression analysis by adjusted by aforementioned variables was performed to determine the impact of statin therapy on the incidence of new-onset DM, IGT, and IFG.

Results; Mean follow-up duration was 534±604 days in all-pt group, and 608±607 days in propensity score matching group. After propensity score match, total 5632 pts (ARB group=2816 and control group = 2816) were enrolled for analysis. Baseline characteristics was similar between the two groups except the more use of diuretics (38% vs. 35.5%, p=0.047). In Kaplan-Meyer curve, there was no difference between the two groups (p=0.428, figure A). Also, in cox-regression analysis performed in all pts, ARB therapy was not associated with the increased incidence of primary end-point (figure B).

Conclusions; In the present study, there was no clear association between ARB therapy and IGT or new-onset DM in a series of cardiovascular pts in Asian population.

Formula

Author Disclosures: J. Park: None. S. Rha: None. J. Choi: None. S. Ryu: None.B. Choi: None. S. Choi: None. S. Im: None. S. Kim: None. J. Na: None. S. Han:None. C. Choi: None. H. Lim: None. J. Kim: None. E. Kim: None. C. Park:None. H. Seo: None. D. Oh: None.


Key Words: Angiotensin II • Drugs

추천 0 공유 · 더보기 목록

댓글 0